Specify a stock or a cryptocurrency in the search bar to get a summary
Alaunos Therapeutics Inc
TCRTAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. Address: 2617 Bissonnet Street, Houston, TX, United States, 77005
Analytics
WallStreet Target Price
1.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TCRT
Dividend Analytics TCRT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TCRT
Stock Valuation TCRT
Financials TCRT
Results | 2019 | Dynamics |